Supporting data for "Platelet-Derived Growth Factor and Middle East Respiratory Syndrome Coronavirus Infection"

Currently, no clinically approved treatment is available for the patients with Middle East respiratory syndrome (MERS). Patients with MERS-CoV infection could receive supportive care only. Due to the high pandemic potential of human coronaviruses and the high mortality rate of MERS-CoV infection, there is a demand to develop MERS-CoV-specific treatment. Here, we examine the role of platelet-derived growth factor receptor (PDGFR) upon MERS-CoV infection and the therapeutic potential of PDGFR inhibitor against MERS. This dataset contains the three main folders, including "Chapter 4", "Chapter 5", and "Chapter 6". Folder "Chapter 4" includes the findings of the assessment of the effect of the PDGFR inhibitor against MERS-CoV infection. Folder "Chapter 5" includes the PDGFR gene knockdown experiment data and the the findings of PDGF signalling pathway modulation during MERS-CoV infection. "Chapter 6" includes the finding of mouse studies, which we infected mice with MERS-CoV and assessed the therapeutic potential of PDGFR inhbitor by providing the treatment (PDGFR inhibitor) to the infected mice. More information is available in the "README" text file.